| Akebia Therapeutics (NASDAQ:AKBA) is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $7.00 price target on the stock. This represents a 194.7% upside from the current price of $2.38. |
| Brunswick (NYSE:BC) is now covered by analysts at Benchmark Co.. They set a “buy” rating and a $70.00 price target on the stock. This represents a 47.0% upside from the current price of $47.62. |
| Corporación América Airports (NYSE:CAAP) is now covered by analysts at Itau BBA Securities. They set an “outperform” rating and a $20.40 price target on the stock. This represents a 3.3% upside from the current price of $19.75. |
| Celldex Therapeutics (NASDAQ:CLDX) is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $64.00 price target on the stock. This represents a 215.8% upside from the current price of $20.27. |
| Co-Diagnostics (NASDAQ:CODX) is now covered by analysts at D. Boral Capital. They set a “buy” rating and a $10.00 price target on the stock. This represents a 2552.5% upside from the current price of $0.38. |
| Columbia Sportswear (NASDAQ:COLM) is now covered by analysts at Barclays PLC. They set an “equal weight” rating and a $64.00 price target on the stock. This represents a 2.1% downside from the current price of $65.40. |
| Corpay (NYSE:CPAY) is now covered by analysts at Oppenheimer Holdings Inc.. They set a “market perform” rating on the stock.The current price is $325.78. |
| Formula One Group (NASDAQ:FWONA) is now covered by analysts at Susquehanna. They set a “positive” rating and a $115.00 price target on the stock. This represents a 44.1% upside from the current price of $79.81. |
| Formula One Group (NASDAQ:FWONK) is now covered by analysts at Susquehanna. They set a “positive” rating and a $115.00 price target on the stock. This represents a 30.6% upside from the current price of $88.08. |
| InvenTrust Properties (NYSE:IVT) is now covered by analysts at BTIG Research. They set a “buy” rating and a $31.00 price target on the stock. This represents a 12.1% upside from the current price of $27.66. |
| LightPath Technologies (NASDAQ:LPTH) is now covered by analysts at Craig Hallum. They set a “buy” rating and a $5.50 price target on the stock. This represents a 126.8% upside from the current price of $2.43. |
| Live Nation Entertainment (NYSE:LYV) is now covered by analysts at Susquehanna. They set a “positive” rating and a $155.00 price target on the stock. This represents a 15.8% upside from the current price of $133.84. |
| MSG Entertainment (NYSE:MSGE) is now covered by analysts at Susquehanna. They set a “positive” rating and a $39.00 price target on the stock. This represents a 18.8% upside from the current price of $32.82. |
| Madison Square Garden Sports (NYSE:MSGS) is now covered by analysts at Susquehanna. They set a “positive” rating and a $254.00 price target on the stock. This represents a 30.1% upside from the current price of $195.25. |
| Symmetry Medical (NYSE:SMA) is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $40.00 price target on the stock. This represents a 19.6% upside from the current price of $33.45. |
| Symmetry Medical (NYSE:SMA) is now covered by analysts at Truist Financial Co.. They set a “buy” rating and a $38.00 price target on the stock. This represents a 13.6% upside from the current price of $33.45. |
| Symmetry Medical (NYSE:SMA) is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $40.00 price target on the stock. This represents a 19.6% upside from the current price of $33.45. |
| Symmetry Medical (NYSE:SMA) is now covered by analysts at Raymond James. They set an “outperform” rating and a $40.00 price target on the stock. This represents a 19.6% upside from the current price of $33.45. |
| Symmetry Medical (NYSE:SMA) is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $38.00 price target on the stock. This represents a 13.6% upside from the current price of $33.45. |
| Symmetry Medical (NYSE:SMA) is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $36.00 price target on the stock. This represents a 7.6% upside from the current price of $33.45. |
| Symmetry Medical (NYSE:SMA) is now covered by analysts at JPMorgan Chase & Co.. They set an “overweight” rating and a $36.00 price target on the stock. This represents a 7.6% upside from the current price of $33.45. |
| Symmetry Medical (NYSE:SMA) is now covered by analysts at Robert W. Baird. They set an “outperform” rating and a $38.00 price target on the stock. This represents a 13.6% upside from the current price of $33.45. |
| Symmetry Medical (NYSE:SMA) is now covered by analysts at KeyCorp. They set an “overweight” rating and a $38.00 price target on the stock. This represents a 13.6% upside from the current price of $33.45. |
| Sphere Entertainment (NYSE:SPHR) is now covered by analysts at Susquehanna. They set a “positive” rating and a $37.00 price target on the stock. This represents a 26.5% upside from the current price of $29.25. |
| TKO Group (NYSE:TKO) is now covered by analysts at Susquehanna. They set a “positive” rating and a $180.00 price target on the stock. This represents a 12.7% upside from the current price of $159.72. |
| Verona Pharma (NASDAQ:VRNA) is now covered by analysts at TD Cowen. They set a “buy” rating and a $100.00 price target on the stock. This represents a 46.3% upside from the current price of $68.37. |
